The Lytic Action of Fresh Human Serum on Bergen A4 Ascites Carcinoma Cells
1904

The Lytic Action of Fresh Human Serum on Bergen A4 Ascites Carcinoma Cells

Sample size: 12 publication Evidence: low

Author Information

Author(s): F. Hartveit

Primary Institution: Gade Institute, Department of Pathology, University of Bergen, Norway

Hypothesis

The study investigates whether the lytic action of fresh human serum on Bergen A4 ascites carcinoma cells is due to sensitization mechanisms other than homograft reactions.

Conclusion

The results suggest that Bergen A4 ascites carcinoma cells, like Ehrlich ascites carcinoma cells, have been sensitized in vivo, indicating the presence of a tumor-specific antigen.

Supporting Evidence

  • The lytic action of fresh human serum on both types of cancer cells was found to be comparable.
  • Bergen A4 ascites carcinoma cells were able to adsorb both oncolytic and haemolytic activity from fresh human serum.
  • The study suggests that the lytic activity is likely due to sensitization mechanisms rather than heterophil antibodies.

Takeaway

The study found that fresh human serum can kill certain cancer cells, and this effect is similar for two different types of cancer cells.

Methodology

The study compared the lytic ability of fresh human serum on two types of cancer cells and tested the serum's activity after adsorption with the cancer cells.

Limitations

Only specific serum samples were tested, and results may not be generalizable to all human sera.

Participant Demographics

Mice used were approximately 4 months old and included hybrids and a closed colony strain.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication